AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Thromboxane A2 receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P21731

UPID:

TA2R_HUMAN

Alternative names:

Prostanoid TP receptor

Alternative UPACC:

P21731; O75228; Q6DK52; Q9UCY1; Q9UCY2

Background:

The Thromboxane A2 receptor, also known as the Prostanoid TP receptor, plays a pivotal role in platelet aggregation and blood clot formation. It operates through a G-protein mediated pathway that activates a phosphatidylinositol-calcium second messenger system, crucial for platelet aggregation. Additionally, it influences renal function by causing vasoconstriction in kidney glomeruli upon activation.

Therapeutic significance:

The association of the Thromboxane A2 receptor with Bleeding disorder, platelet-type, 13, underscores its therapeutic potential. Targeting this receptor could lead to innovative treatments for disorders characterized by impaired platelet aggregation, offering hope for patients with bleeding disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.